Funding for this research was provided by:
Vaincre La Mucoviscidose (RF20180502264)
Agence Nationale de la Recherche (ANR-13-BSV1-0019-02)
Received: 1 August 2021
Accepted: 28 February 2022
First Online: 12 April 2022
: MFDC, IP, AS, CS, SM, DV, MC, G C, FB, GP, RF, CHC, NO, JPJ, CGP, PZ, AH, FO, and AE do not declare any potential financial and non-financial competing interest. ISG declares following fundings from Vertex Pharmaceuticals: Innovation Award funding program 2016, 2017 and 2019. She was PI in clinical trials from Vertex Pharmaceuticals and took part to scientific advisory boards organized by Vertex Pharmaceuticals, Eloxx and Proteostasis Therapeutics.